Oppenheimer analyst Jeff Jones lowered the firm’s price target on Ventyx Biosciences to $62 from $65 and keeps an Outperform rating on the shares. Ventyx management on Thursday provided a year-end business update, highlighting ongoing clinical trials for three different candidates, with an additional candidate, VTX3232, anticipated to begin Phase 1 in the first half of 2023, the analyst tells investors in a research note.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on VTYX:
- Ventyx Biosciences to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
- Ventyx Biosciences reports Q4 EPS (62c), consensus (64c)
- Ventyx Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Recent Corporate Progress
- Wells starts Ventyx at Overweight, sees multiple catalysts in next 12-18 months
- Ventyx Biosciences initiated with an Overweight at Wells Fargo
